Imunon’s (IMNN) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Imunon (NASDAQ:IMNN) in a report issued on Wednesday,Benzinga reports. The firm currently has a $12.00 price target on the stock.

Several other equities analysts also recently issued reports on the stock. D. Boral Capital reaffirmed a “buy” rating and set a $29.00 price objective on shares of Imunon in a report on Tuesday. EF Hutton Acquisition Co. I raised Imunon to a “strong-buy” rating in a report on Monday, September 23rd.

Imunon Price Performance

Imunon stock opened at $0.84 on Wednesday. Imunon has a 12 month low of $0.48 and a 12 month high of $3.65. The stock has a market capitalization of $12.25 million, a PE ratio of -0.44 and a beta of 2.12. The business has a 50 day simple moving average of $0.89 and a 200-day simple moving average of $1.10.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.